Alzinova: Updated in-depth analysis of phase Ib data - Redeye

Redeye leaves a comment following Alzinova’s announcement of updated in-depth analysis of data from part A of Alzinova's phase 1b study with the vaccine candidate ALZ-101. We are encouraged to learn that patients who experienced elevated antibody levels after treatment respond positively to biomarkers associated with Alzheimer's disease.

Länk till analysen i sin helhet: https://www.redeye.se/research/995256/alzinova-updated-in-depth-analysis-of-phase-ib-data?utm_source=finwire&utm_medium=RSS